L. Wyrwicz

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Background The PD-1 inhibitor pembrolizumab has shown robust clinical activity in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H)...

M. Gumus ;

J. Bae Ahn ;

L. Wyrwicz ;

M. Kwiatkowski ;

J. Kim ;

S. Yalcin ;

M. Sendur ;

A. Odeleye-Ajakaye ;

P. Leconte ;

T. Andre ;

T. Kim ;

D. Fogelman ;

C. Sposetti ;

06/27/2022

Correlation between extramural vascular invasion (EMVI) and systemic inflammatory response markers in rectal cancer

Background Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. Rectal cancer constitutes around one-third of all CRCs. The current standard o...

L. Wyrwicz ;

Cieszymierz Gawiński ;

Anna Hołdakowska ;

06/27/2022

Lucjan Wyrwicz, MD, Maria Sklodowska Curie National Cancer Research Institute

Videos

Continued Benefit From Pembrolizumab Plus Chemotherapy in Later-Line Therapy for Patients With Advanced, HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma

07/12/2023

L. Wyrwicz ;

At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...

At the 2023 World Congress on...

07/12/2023

Oncology